Gene Therapy for Familial Hypercholesterolemia

Current Pharmaceutical Design

Volumn 17, Issue 24, 2011, Pages 2575-2591

  van Craeyveld, Eline ^a   Jacobs, Frank ^a   Gordts, Stephanie C ^a   de Geest, Bart ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Atherosclerosis; Familial hypercholesterolemia; Gene therapy; Low density lipoprotein receptor gene transfer

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANGIOCARDIOGRAPHY; ANIMAL MODEL; AORTA VALVE REGURGITATION; ATHEROSCLEROSIS; DIET RESTRICTION; DISEASE COURSE; DRUG MEGADOSE; FAMILIAL HYPERCHOLESTEROLEMIA; FIBROSIS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE THERAPY; GENE TRANSFER; GRAFT REJECTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART TRANSPLANTATION; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIVER CELL; LIVER TRANSPLANTATION; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLASMAPHERESIS; PRIORITY JOURNAL; RABBIT; REMISSION; REVIEW; SAFETY; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL, LDL; DISEASE MODELS, ANIMAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; RECEPTORS, LDL;

EID: 80053520295     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211797247550     Document Type: Review

References (194)

1. Müller C. Xanthomata, hypercholesterolemia, angina pectoris. Acta Medica Scandinavia 1938; 89: 75-84.
2. Khachadurian AK. The Inheritance of Essential Familial Hypercholesterolemia. The American journal of medicine 1964; 37: 402-7.
3. Brown MS and Goldstein JL. Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Proceedings of the National Academy of Sciences of the United States of America 1974; 71: 788-92.
4. Brown MS and Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
5. Goldstein JL and Brown MS. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3- methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci USA 1973; 70: 2804-8.
6. Austin MA, Hutter CM, Zimmern RL, and Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. American journal of epidemiology 2004; 160: 407-20.
7. Marks D, Thorogood M, Neil HA, and Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003; 168: 1-14.
8. Rahalkar AR and Hegele RA. Monogenic pediatric dyslipidemias: classification, genetics and clinical spectrum. Molecular genetics and metabolism 2008; 93: 282-94.
9. Kwiterovich PO, Jr., Fredrickson DS, and Levy RI. Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. The Journal of clinical investigation 1974; 53: 1237-49.
10. Leonard JV, Whitelaw AG, Wolff OH, Lloyd JK, and Slack J. Diagnosing familial hypercholesterolaemia in childhood by measuring serum cholesterol. British medical journal 1977; 1: 1566-8.
11. Kidambi S and Patel SB. Sitosterolaemia: pathophysiology, clinical presentation and laboratory diagnosis. Journal of clinical pathology 2008; 61: 588-94.
12. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. The American journal of cardiology 1993; 72: 171-6.
13. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ (Clinical research ed 1991; 303: 893-6.
14. Fouchier SW, Defesche JC, Umans-Eckenhausen MW, and Kastelein JP. The molecular basis of familial hypercholesterolemia in The Netherlands. Human genetics 2001; 109: 602-15.
15. Heath KE, Gudnason V, Humphries SE, and Seed M. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. Atherosclerosis 1999; 143: 41-54.
16. Marang van de Mheen PJ, ten Asbroek AH, Bonneux L, Bonsel GJ, and Klazinga NS. Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands. European heart journal 2002; 23: 1922-30.
17. Koeijvoets KC, Wiegman A, Rodenburg J, et al. Effect of lowdensity lipoprotein receptor mutation on lipoproteins and cardiovascular disease risk: a parent-offspring study. Atherosclerosis 2005; 180: 93-9.
18. Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. Journal of internal medicine 2004; 256: 482-90.
19. Tonstad S, Joakimsen O, Stensland-Bugge E, et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arteriosclerosis, thrombosis, and vascular biology 1996; 16: 984-91.
20. Aggoun Y, Bonnet D, Sidi D, et al. Arterial mechanical changes in children with familial hypercholesterolemia. Arteriosclerosis, thrombosis, and vascular biology 2000; 20: 2070-5.
21. de Jongh S, Lilien MR, Bakker HD, et al. Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia. Atherosclerosis 2002; 163: 193-7.
22. Austin MA, Hutter CM, Zimmern RL, and Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. American journal of epidemiology 2004; 160: 421-9.
23. Bhatnagar D, Morgan J, Siddiq S, et al. Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. Bmj 2000; 321: 1497-500.
24. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 1969; 2: 1380-2.
25. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 1999; 142: 105-12.
26. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ (Clinical research ed 2008; 337: a2423.
27. Hutter CM, Austin MA, and Humphries SE. Familial hypercholesterolemia, peripheral arterial disease, and stroke: a HuGE minireview. American journal of epidemiology 2004; 160: 430-5.
28. Postiglione A, Rubba P, De Simone B, et al. Carotid atherosclerosis in familial hypercholesterolemia. Stroke; a journal of cerebral circulation 1985; 16: 658-61.
29. Kroon AA, Ajubi N, van Asten WN, and Stalenhoef AF. The prevalence of peripheral vascular disease in familial hypercholesterolaemia. Journal of internal medicine 1995; 238: 451-9.
30. Durrington P. Dyslipidaemia. Lancet 2003; 362: 717-31.
31. de Groot E, Hovingh GK, Wiegman A, et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 2004; 109: III33-8.
32. Wittekoek ME, de Groot E, Prins MH, et al. Differences in intimamedia thickness in the carotid and femoral arteries in familial hypercholesterolemic heterozygotes with and without clinical manifestations of cardiovascular disease. Atherosclerosis 1999; 146: 271-9.
33. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357: 577-81.
34. Buja LM, Kovanen PT, and Bilheimer DW. Cellular pathology of homozygous familial hypercholesterolemia. The American journal of pathology 1979; 97: 327-57.
35. Kawaguchi A, Miyatake K, Yutani C, et al. Characteristic cardiovascular manifestation in homozygous and heterozygous familial hypercholesterolemia. American heart journal 1999; 137: 410-8.
36. Schlant R, Alsiander R, and Hurst W, The heart. 1994, New York: Mc Graw Hill.
37. Kawaguchi A, Yutani C, and Yamamoto A. Hypercholesterolemic valvulopathy: an aspect of malignant atherosclerosis. Ther Apher Dial 2003; 7: 439-43.
38. Awan Z, Alrasadi K, Francis GA, et al. Vascular calcifications in homozygote familial hypercholesterolemia. Arteriosclerosis, thrombosis, and vascular biology 2008; 28: 777-85.
39. Kolansky DM, Cuchel M, Clark BJ, et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. The American journal of cardiology 2008; 102: 1438-43.
40. Jeon H and Blacklow SC. Structure and physiologic function of the low-density lipoprotein receptor. Annu Rev Biochem 2005; 74: 535-62.
41. Hussain M. Structural, biochemical and signaling properties of the low-density lipoprotein receptor gene family. Front Biosci 2001; 6: D417-28.
42. Hussain MM, Strickland DK, and Bakillah A. The mammalian low-density lipoprotein receptor family. Annu Rev Nutr 1999; 19: 141-72.
43. Nimpf J and Schneider WJ. From cholesterol transport to signal transduction: low density lipoprotein receptor, very low density lipoprotein receptor, and apolipoprotein E receptor-2. Biochim Biophys Acta 2000; 1529: 287-98.
44. Yamamoto T, Davis CG, Brown MS, et al. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell 1984; 39: 27-38.
45. Li Y, Lu W, Schwartz AL, and Bu G. Receptor-associated protein facilitates proper folding and maturation of the low-density lipoprotein receptor and its class 2 mutants. Biochemistry 2002; 41: 4921-8.
46. Beglova N and Blacklow SC. The LDL receptor: how acid pulls the trigger. Trends in biochemical sciences 2005; 30: 309-17.
47. Innerarity TL and Mahley RW. Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry 1978; 17: 1440-7.
48. Davis CG, van Driel IR, Russell DW, Brown MS, and Goldstein JL. The low density lipoprotein receptor. Identification of amino acids in cytoplasmic domain required for rapid endocytosis. The Journal of biological chemistry 1987; 262: 4075-82.
49. Brown MS, Herz J, and Goldstein JL. LDL-receptor structure. Calcium cages, acid baths and recycling receptors. Nature 1997; 388: 629-30.
50. Nicholls P, Young IS, and Graham CA. Genotype/phenotype correlations in familial hypercholesterolaemia. Curr Opin Lipidol 1998; 9: 313-7.
51. Hobbs HH, Brown MS, and Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992; 1: 445-66.
52. Wilson DJ, Gahan M, Haddad L, et al. A World Wide Web site for low-density lipoprotein receptor gene mutations in familial hypercholesterolemia: sequence-based, tabular, and direct submission data handling. Am J Cardiol 1998; 81: 1509-11.
53. Villeger L, Abifadel M, Allard D, et al. The UMD-LDLR database: additions to the software and 490 new entries to the database. Hum Mutat 2002; 20: 81-7.
54. Sudhof TC, Van der Westhuyzen DR, Goldstein JL, Brown MS, and Russell DW. Three direct repeats and a TATA-like sequence are required for regulated expression of the human low density lipoprotein receptor gene. J Biol Chem 1987; 262: 10773-9.
55. L. An update on familial hypercholesterolaemia. Ann Med 1999; 31 Suppl 1: 13-8.
56. Smith JR, Osborne TF, Goldstein JL, and Brown MS. Identification of nucleotides responsible for enhancer activity of sterol regulatory element in low density lipoprotein receptor gene. J Biol Chem 1990; 265: 2306-10.
57. Kong WJ, Liu J, and Jiang JD. Human low-density lipoprotein receptor gene and its regulation. J Mol Med 2006; 84: 29-36.
58. Horton JD, Goldstein JL, and Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-31.
59. Goldstein JL, DeBose-Boyd RA, and Brown MS. Protein sensors for membrane sterols. Cell 2006; 124: 35-46.
60. Radhakrishnan A, Ikeda Y, Kwon HJ, Brown MS, and Goldstein JL. From the Cover: Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: Oxysterols block transport by binding to Insig. Proc Natl Acad Sci USA 2007; 104: 6511-8.
61. Sun LP, Seemann J, Goldstein JL, and Brown MS. From the Cover: Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: Insig renders sorting signal in Scap inaccessible to COPII proteins. Proc Natl Acad Sci USA 2007; 104: 6519-26.
62. Hodgin JB and Maeda N. Minireview: estrogen and mouse models of atherosclerosis. Endocrinology 2002; 143: 4495-501.
63. Inukai T, Takanashi K, Takebayashi K, et al. Estrogen markedly increases LDL-receptor activity in hypercholesterolemic patients. J Med 2000; 31: 247-61.
64. Bruning JC, Lingohr P, Gillette J, et al. Estrogen receptor-alpha and Sp1 interact in the induction of the low density lipoproteinreceptor. J Steroid Biochem Mol Biol 2003; 86: 113-21.
65. Twisk J, Gillian-Daniel DL, Tebon A, et al. The role of the LDL receptor in apolipoprotein B secretion. J Clin Invest 2000; 105: 521-32.
66. Hornick CA, Kita T, Hamilton RL, Kane JP, and Havel RJ. Secretion of lipoproteins from the liver of normal and Watanabe heritable hyperlipidemic rabbits. Proceedings of the National Academy of Sciences of the United States of America 1983; 80: 6096-100.
67. Parhofer KG and Barrett PH. Thematic review series: patientoriented research. What we have learned about VLDL and LDL metabolism from human kinetics studies. Journal of lipid research 2006; 47: 1620-30.
68. Cummings MH, Watts GF, Umpleby M, et al. Increased hepatic secretion of very-low-density-lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study. Atherosclerosis 1995; 113: 79-89.
69. Tremblay AJ, Lamarche B, Ruel IL, et al. Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation. J Lipid Res 2004; 45: 866-72.
70. Fisher WR, Zech LA, and Stacpoole PW. ApoB metabolism in familial hypercholesterolemia. Inconsistencies with the LDL receptor paradigm. Arterioscler Thromb 1994; 14: 501-10.
71. James RW, Martin B, Pometta D, et al. Apolipoprotein B metabolism in homozygous familial hypercholesterolemia. Journal of lipid research 1989; 30: 159-69.
72. Millar JS, Maugeais C, Ikewaki K, et al. Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production. Arteriosclerosis, thrombosis, and vascular biology 2005; 25: 560-5.
73. Maugeais C, Ouguerram K, Frenais R, et al. Effect of low-density lipoprotein apheresis on kinetics of apolipoprotein B in heterozygous familial hypercholesterolemia. J Clin Endocrinol Metab 2001; 86: 1679-86.
74. Goldberg RB, Fless GM, Baker SG, et al. Abnormalities of high density lipoproteins in homozygous familial hypercholesterolemia. Arteriosclerosis Dallas, Tex 1984; 4: 472-8.
75. Keidar S, Ostlund RE, Jr., and Schonfeld G. Apolipoprotein E-rich HDL in patients with homozygous familial hypercholesterolemia. Atherosclerosis 1990; 84: 155-63.
76. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004; 173: 55-68.
77. Huijgen R, Vissers MN, Defesche JC, et al. Familial hypercholesterolemia: current treatment and advances in management. Expert review of cardiovascular therapy 2008; 6: 567-81.
78. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
79. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. The New England journal of medicine 1998; 339: 1349-57.
80. Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370: 1829-39.
81. Rader DJ, Cohen J, and Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. The Journal of clinical investigation 2003; 111: 1795-803.
82. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. The New England journal of medicine 2008; 358: 1431-43.
83. Stacpoole PW, von Bergmann K, Kilgore LL, Zech LA, and Fisher WR. Nutritional regulation of cholesterol synthesis and apolipoprotein B kinetics: studies in patients with familial hypercholesterolemia and normal subjects treated with a high carbohydrate, low fat diet. Journal of lipid research 1991; 32: 1837-48.
84. Naoumova RP, Thompson GR, and Soutar AK. Current management of severe homozygous hypercholesterolaemias. Current opinion in lipidology 2004; 15: 413-22.
85. Thompson GR. Recommendations for the use of LDL apheresis. Atherosclerosis 2008; 198: 247-55.
86. Hopkins PN. Familial hypercholesterolemia--improving treatment and meeting guidelines. International journal of cardiology 2003; 89: 13-23.
87. Marais AD, Naoumova RP, Firth JC, et al. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. Journal of lipid research 1997; 38: 2071-8.
88. Gagne C, Gaudet D, and Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002; 105: 2469-75.
89. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. The New England journal of medicine 2007; 356: 148-56.
90. Kawagishi N, Satoh K, Akamatsu Y, et al. Long-term outcome after living donor liver transplantation for two cases of homozygous familial hypercholesterolemia from a heterozygous donor. Journal of atherosclerosis and thrombosis 2007; 14: 94-8.
91. Grossman M, Rader DJ, Muller DW, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nature medicine 1995; 1: 1148-54.
92. Van Craeyveld E, Gordts S, Jacobs F, and De Geest B. Gene therapy to improve high-density lipoprotein metabolism and function. Curr Pharm Des 2010; 16: 1531-44.
93. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993; 34: 1255-74.
94. Paigen B, Ishida BY, Verstuyft J, Winters RB, and Albee D. Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice. Arteriosclerosis 1990; 10: 316-23.
95. Ishibashi S, Brown MS, Goldstein JL, et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92: 883-93.
96. Veniant MM, Withycombe S, and Young SG. Lipoprotein size and atherosclerosis susceptibility in Apoe(-/-) and Ldlr(-/-) mice. Arterioscler Thromb Vasc Biol 2001; 21: 1567-70.
97. Ishibashi S, Goldstein JL, Brown MS, Herz J, and Burns DK. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest 1994; 93: 1885-93.
98. Davidson NO and Shelness GS. APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu Rev Nutr 2000; 20: 169-93.
99. Ishibashi S, Herz J, Maeda N, Goldstein JL, and Brown MS. The two-receptor model of lipoprotein clearance: tests of the hypothesis in knockout mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc Natl Acad Sci USA 1994; 91: 4431-5.
100. Herz J and Willnow TE. Lipoprotein and receptor interactions in vivo. Curr Opin Lipidol 1995; 6: 97-103.
101. Powell-Braxton L, Veniant M, Latvala RD, et al. A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet. Nat Med 1998; 4: 934-8.
102. Veniant MM, Pierotti V, Newland D, et al. Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. J Clin Invest 1997; 100: 180-8.
103. Greeve J, Altkemper I, Dieterich JH, Greten H, and Windler E. Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J Lipid Res 1993; 34: 1367-83.
104. Nagashima M, McLean JW, and Lawn RM. Cloning and mRNA tissue distribution of rabbit cholesteryl ester transfer protein. J Lipid Res 1988; 29: 1643-9.
105. Shore B and Shore V. Rabbits as a model for the study of hyperlipoproteinemia and atherosclerosis. Adv Exp Med Biol 1976; 67: 123-41.
106. Chapman MJ. Animal lipoproteins: chemistry, structure, and comparative aspects. J Lipid Res 1980; 21: 789-853.
107. Warren RJ, Ebert DL, Mitchell A, and Barter PJ. Rabbit hepatic lipase cDNA sequence: low activity is associated with low messenger RNA levels. J Lipid Res 1991; 32: 1333-9.
108. Spady DK, Huettinger M, Bilheimer DW, and Dietschy JM. Role of receptor-independent low density lipoprotein transport in the maintenance of tissue cholesterol balance in the normal and WHHL rabbit. J Lipid Res 1987; 28: 32-41.
109. Esper E, Chan EK, and Buchwald H. Natural history of atherosclerosis and hyperlipidemia in heterozygous WHHL (WHHL-Hh) rabbits. I. The effects of aging and gender on plasma lipids and lipoproteins. J Lab Clin Med 1993; 121: 97-102.
110. Esper E, Runge WJ, Gunther R, and Buchwald H. Natural history of atherosclerosis and hyperlipidemia in heterozygous WHHL (WHHL-Hh) rabbits. II. Morphologic evaluation of spontaneously occurring aortic and coronary lesions. J Lab Clin Med 1993; 121: 103-10.
111. Van Craeyveld E, Lievens J, Jacobs F, et al. Apolipoprotein A-I and lecithin:cholesterol acyltransferase transfer induce cholesterol unloading in complex atherosclerotic lesions. Gene Ther 2009; 16: 757-65.
112. Atkinson JB, Hoover RL, Berry KK, and Swift LL. Cholesterol-fed heterozygous Watanabe heritable hyperlipidemic rabbits: a new model for atherosclerosis. Atherosclerosis 1989; 78: 123-36.
113. Van Craeyveld E, Jacobs F, Feng Y, et al. The relative atherogenicity of VLDL and LDL is dependent on the topographic site. J Lipid Res 2010; 51: 1478-85.
114. Jacobs F, Van Craeyveld E, Feng Y, and De Geest B. The diameter of liver sinusoidal fenestrae is not a major determinant of lipoprotein levels and atherosclerosis in cholesterol-fed rabbits. Cardiovasc Pathol 2011; 20: 44-50.
115. Kondo T and Watanabe Y. A heritable hyperlipemic rabbit (author's transl)]. Jikken Dobutsu 1975; 24: 89-94.
116. Watanabe Y. Serial inbreeding of rabbits with hereditary hyperlipidemia (WHHL- rabbit). Atherosclerosis 1980; 36: 261-8.
117. Yamamoto T, Bishop RW, Brown MS, Goldstein JL, and Russell DW. Deletion in cysteine-rich region of LDL receptor impedes transport to cell surface in WHHL rabbit. Science 1986; 232: 1230-7.
118. Shiomi M, Ito T, Fujioka T, and Tsujita Y. Age-associated decrease in plasma cholesterol and changes in cholesterol metabolism in homozygous Watanabe heritable hyperlipidemic rabbits. Metabolism: clinical and experimental 2000; 49: 552-6.
119. Gallagher PJ, Nanjee MN, Richards T, Roche WR, and Miller NE. Biochemical and pathological features of a modified strain of Watanabe heritable hyperlipidaemic rabbits. Atherosclerosis 1988; 71: 173-83.
120. Saku K, Yamamoto K, Sakai T, et al. Kinetics of HDL-apo A-I in the WHHL rabbit, an animal model of familial hypercholesterolemia. Atherosclerosis 1989; 79: 225-30.
121. Son YS and Zilversmit DB. Increased lipid transfer activities in hyperlipidemic rabbit plasma. Arteriosclerosis Dallas, Tex 1986; 6: 345-51.
122. Jacobs F, Wisse E, and De Geest B. The role of liver sinusoidal cells in hepatocyte-directed gene transfer. Am J Pathol 2010; 176: 14-21.
123. Kuzmin AI, Finegold MJ, and Eisensmith RC. Macrophage depletion increases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo. Gene Ther 1997; 4: 309-16.
124. Wolff G, Worgall S, van Rooijen N, et al. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol 1997; 71: 624-9.
125. Schiedner G, Hertel S, Johnston M, et al. Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors. Mol Ther 2003; 7: 35-43.
126. Snoeys J, Mertens G, Lievens J, et al. Lipid emulsions potently increase transgene expression in hepatocytes after adenoviral transfer. Mol Ther 2006; 13: 98-107.
127. Wisse E. An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids. J Ultrastruct Res 1970; 31: 125-50.
128. Wisse E. An ultrastructural characterization of the endothelial cell in the rat liver sinusoid under normal and various experimental conditions, as a contribution to the distinction between endothelial and Kupffer cells. J Ultrastruct Res 1972; 38: 528-62.
129. Jacobs F, Feng Y, Van Craeyveld E, et al. Species differences in hepatocyte-directed gene transfer: implications for clinical translation. Curr Gene Ther 2009; 9: 83-90.
130. Wisse E, De Zanger RB, Charels K, Van Der Smissen P, and McCuskey RS. The liver sieve: considerations concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of Disse. Hepatology 1985; 5: 683-92.
131. Snoeys J, Lievens J, Wisse E, et al. Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestrae. Gene Ther 2007; 14: 604-12.
132. Lievens J, Snoeys J, Vekemans K, et al. The size of sinusoidal fenestrae is a critical determinant of hepatocyte transduction after adenoviral gene transfer. Gene Ther 2004; 11: 1523-31.
133. Wisse E, Jacobs F, Topal B, Frederik P, and De Geest B. The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer. Gene Ther 2008; 15: 1193-9.
134. Chen H. Comparative observation of the recombinant adenoassociated virus 2 using transmission electron microscopy and atomic force microscopy. Microsc Microanal 2007; 13: 384-9.
135. Szilagyi JF and Berriman J. Herpes simplex virus L particles contain spherical membrane-enclosed inclusion vesicles. J Gen Virol 1994; 75 (Pt 7): 1749-53.
136. Jacobs F, Van Craeyveld E, and De Geest B. Why the diameter of sinusoidal fenestrae unlikely matters for lipoprotein metabolism and atherosclerosis susceptibility. Cardiovasc Pathol 2011; 20: 193-4.
137. Wilson JM, Chowdhury NR, Grossman M, et al. Temporary amelioration of hyperlipidemia in low density lipoprotein receptordeficient rabbits transplanted with genetically modified hepatocytes. Proceedings of the National Academy of Sciences of the United States of America 1990; 87: 8437-41.
138. Chowdhury JR, Grossman M, Gupta S, et al. Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. Science New York, N.Y 1991; 254: 1802-5.
139. Grossman M, Wilson JM, and Raper SE. A novel approach for introducing hepatocytes into the portal circulation. J Lab Clin Med 1993; 121: 472-8.
140. Grossman M, Raper SE, and Wilson JM. Transplantation of genetically modified autologous hepatocytes into nonhuman primates: feasibility and short-term toxicity. Hum Gene Ther 1992; 3: 501-10.
141. Wilson JM, Grossman M, Raper SE, et al. Ex vivo gene therapy of familial hypercholesterolemia. Hum Gene Ther 1992; 3: 179-222.
142. Grossman M, Raper SE, and Wilson JM. Towards liver-directed gene therapy: retrovirus-mediated gene transfer into human hepatocytes. Somat Cell Mol Genet 1991; 17: 601-7.
143. Grossman M, Raper SE, Kozarsky K, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 1994; 6: 335-41.
144. Raper SE, Grossman M, Rader DJ, et al. Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia. Ann Surg 1996; 223: 116-26.
145. Al-Allaf FA, Coutelle C, Waddington SN, et al. LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives. Int Arch Med; 3: 36.
146. Wilson JM, Grossman M, Wu CH, et al. Hepatocyte-directed gene transfer in vivo leads to transient improvement of hypercholesterolemia in low density lipoprotein receptor-deficient rabbits. The Journal of biological chemistry 1992; 267: 963-7.
147. Kozarsky KF, McKinley DR, Austin LL, et al. In vivo correction of low density lipoprotein receptor deficiency in the Watanabe heritable hyperlipidemic rabbit with recombinant adenoviruses. J Biol Chem 1994; 269: 13695-702.
148. Li J, Fang B, Eisensmith RC, et al. In vivo gene therapy for hyperlipidemia: phenotypic correction in Watanabe rabbits by hepatic delivery of the rabbit LDL receptor gene. J Clin Invest 1995; 95: 768-73.
149. Kobayashi K, Oka K, Forte T, et al. Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor. J Biol Chem 1996; 271: 6852-60.
150. Kozarsky KF, Jooss K, Donahee M, Strauss JF, 3rd, and Wilson JM. Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene. Nat Genet 1996; 13: 54-62.
151. Yang Y, Ertl HC, and Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1: 433-42.
152. Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-11.
153. O'Neal WK, Zhou H, Morral N, et al. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. Mol Med 2000; 6: 179-95.
154. De Geest B, Van Linthout S, Lox M, Collen D, and Holvoet P. Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer. Hum Gene Ther 2000; 11: 101-12.
155. De Geest B, Van Linthout S, and Collen D. Sustained expression of human apo A-I following adenoviral gene transfer in mice. Gene Ther 2001; 8: 121-7.
156. Van Linthout S, Collen D, and De Geest B. Effect of promoters and enhancers on expression, transgene DNA persistence, and hepatotoxicity after adenoviral gene transfer of human apolipoprotein A-I. Hum Gene Ther 2002; 13: 829-40.
157. Van Linthout S, Lusky M, Collen D, and De Geest B. Persistent hepatic expression of human apo A-I after transfer with a helpervirus independent adenoviral vector. Gene Ther 2002; 9: 1520-8.
158. Pakkanen TM, Laitinen M, Hippelainen M, et al. Enhanced plasma cholesterol lowering effect of retrovirus-mediated LDL receptor gene transfer to WHHL rabbit liver after improved surgical technique and stimulation of hepatocyte proliferation by combined partial liver resection and thymidine kinase--ganciclovir treatment. Gene Ther 1999; 6: 34-41.
159. Tomita N, Morishita R, Koike H, et al. Therapeutic approach to familial hypercholesterolemia by HVJ-liposomes in LDL receptor knockout mouse. Int J Mol Med 2002; 10: 137-43.
160. Shichiri M, Tanaka A, and Hirata Y. Intravenous gene therapy for familial hypercholesterolemia using ligand-facilitated transfer of a liposome:LDL receptor gene complex. Gene Ther 2003; 10: 827-31.
161. Jacobs F, Van Craeyveld E, Feng Y, Snoeys J, and De Geest B. Adenoviral low density lipoprotein receptor attenuates progression of atherosclerosis and decreases tissue cholesterol levels in a murine model of familial hypercholesterolemia. Atherosclerosis 2008; 201: 289-97.
162. Cichon G, Willnow T, Herwig S, et al. Non-physiological overexpression of the low density lipoprotein receptor (LDLr) gene in the liver induces pathological intracellular lipid and cholesterol storage. J Gene Med 2004; 6: 166-75.
163. Hibbitt OC, McNeil E, Lufino MM, et al. Long-term physiologically regulated expression of the low-density lipoprotein receptor in vivo using genomic DNA mini-gene constructs. Mol Ther; 18: 317-26.
164. De Geest BR, Van Linthout SA, and Collen D. Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigenpresenting cells. Blood 2003; 101: 2551-6.
165. Pastore L, Morral N, Zhou H, et al. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther 1999; 10: 1773-81.
166. Mingozzi F, Liu YL, Dobrzynski E, et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 2003; 111: 1347-56.
167. Franco LM, Sun B, Yang X, et al. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther 2005; 12: 876-84.
168. Al-Dosari M, Zhang G, Knapp JE, and Liu D. Evaluation of viral and mammalian promoters for driving transgene expression in mouse liver. Biochem Biophys Res Commun 2006; 339: 673-8.
169. Guo ZS, Wang LH, Eisensmith RC, and Woo SL. Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer. Gene Ther 1996; 3: 802-10.
170. Kankkonen HM, Vahakangas E, Marr RA, et al. Long-term lowering of plasma cholesterol levels in LDL-receptor-deficient WHHL rabbits by gene therapy. Mol Ther 2004; 9: 548-56.
171. Wang L, Calcedo R, Nichols TC, et al. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood 2005; 105: 3079-86.
172. Brinster RL, Allen JM, Behringer RR, Gelinas RE, and Palmiter RD. Introns increase transcriptional efficiency in transgenic mice. Proc Natl Acad Sci USA 1988; 85: 836-40.
173. Liu K, Sandgren EP, Palmiter RD, and Stein A. Rat growth hormone gene introns stimulate nucleosome alignment in vitro and in transgenic mice. Proc Natl Acad Sci USA 1995; 92: 7724-8.
174. Miao CH, Ohashi K, Patijn GA, et al. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol Ther 2000; 1: 522-32.
175. Palmiter RD, Sandgren EP, Avarbock MR, Allen DD, and Brinster RL. Heterologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci USA 1991; 88: 478-82.
176. Agarwal M, Austin TW, Morel F, et al. Scaffold attachment region-mediated enhancement of retroviral vector expression in primary T cells. J Virol 1998; 72: 3720-8.
177. Auten J, Agarwal M, Chen J, Sutton R, and Plavec I. Effect of scaffold attachment region on transgene expression in retrovirus vector-transduced primary T cells and macrophages. Hum Gene Ther 1999; 10: 1389-99.
178. Dang Q, Auten J, and Plavec I. Human beta interferon scaffold attachment region inhibits de novo methylation and confers longterm, copy number-dependent expression to a retroviral vector. J Virol 2000; 74: 2671-8.
179. Miao CH, Thompson AR, Loeb K, and Ye X. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. Mol Ther 2001; 3: 947-57.
180. Schiedner G, Hertel S, Johnston M, et al. Variables affecting in vivo performance of high-capacity adenovirus vectors. J Virol 2002; 76: 1600-9.
181. De Geest B, Zhao Z, Collen D, and Holvoet P. Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice. Circulation 1997; 96: 4349-56.
182. Jacobs F, Snoeys J, Feng Y, et al. Direct comparison of hepatocytespecific expression cassettes following adenoviral and nonviral hydrodynamic gene transfer. Gene Ther 2008; 15: 594-603.
183. Chen SJ, Rader DJ, Tazelaar J, et al. Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor. Mol Ther 2000; 2: 256-61.
184. Oka K, Pastore L, Kim IH, et al. Long-term stable correction of low-density lipoprotein receptor- deficient mice with a helperdependent adenoviral vector expressing the very low-density lipoprotein receptor. Circulation 2001; 103: 1274-81.
185. Nomura S, Merched A, Nour E, et al. Low-density lipoprotein receptor gene therapy using helper-dependent adenovirus produces long-term protection against atherosclerosis in a mouse model of familial hypercholesterolemia. Gene Ther 2004; 11: 1540-8.
186. Lebherz C, Gao G, Louboutin JP, et al. Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. J Gene Med 2004; 6: 663-72.
187. Belalcazar LM, Merched A, Carr B, et al. Long-term stable expression of human apolipoprotein A-I mediated by helperdependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia. Circulation 2003; 107: 2726-32.
188. Feng Y, Jacobs F, Van Craeyveld E, et al. Human ApoA-I transfer attenuates transplant arteriosclerosis via enhanced incorporation of bone marrow-derived endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008; 28: 278-83.
189. Feng Y, van Eck M, Van Craeyveld E, et al. Critical role of scavenger receptor-BI-expressing bone marrow-derived endothelial progenitor cells in the attenuation of allograft vasculopathy after human apo A-I transfer. Blood 2009; 113: 755-64.
190. Feng Y, Van Craeyveld E, Jacobs F, et al. Wild-type apo A-I and apo A-I(Milano) gene transfer reduce native and transplant arteriosclerosis to a similar extent. J Mol Med 2009; 87: 287-97.
191. Feng Y, Gordts SC, Chen F, et al. Topical HDL administration reduces vein graft atherosclerosis in apo E deficient mice. Atherosclerosis 2010; 214: 271-8.
192. Kassim SH, Li H, Vandenberghe LH, et al. Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis. PLoS One; 5: e13424.
193. Van Craeyveld E, Gordts SC, Nefyodova E, Jacobs F, and De Geest B. Regression and stabilization of advanced murine atherosclerotic lesions: a comparison of LDL lowering and HDL raising gene transfer strategies. J Mol Med 2011; 89: 555-67.
194. MacDougall ED, Kramer F, Polinsky P, et al. Aggressive very lowdensity lipoprotein (VLDL) and LDL lowering by gene transfer of the VLDL receptor combined with a low-fat diet regimen induces regression and reduces macrophage content in advanced atherosclerotic lesions in LDL receptor-deficient mice. Am J Pathol 2006; 168: 2064-73.